Vol. 47 No. 8

Urologists face a significant risk of on-the-job pain and injury, an exclusive Urology Times survey has found.

The treatment provides an alternative to simple prostatectomy in men with large prostates.

Injury stemming from awkward maneuvers and equipment can and should be prevented, says Henry Rosevear, MD.

Results of a phase III trial show the benefit of darolutamide (Nubeqa) in reducing the risk of metastases or death compared with placebo in men with nonmetastatic castration-resistant prostate cancer.

Work out decisions on combined accounts and long-term goals before the big day, advises Jeff Witz, CFP.